SABCS 2022 | Systemic immune response to durvalumab concomitant with neoadjuvant chemotherapy in early stage TNCB

Kim Blenman, PhD, MS, Yale School of Medicine, New Haven, CT, talks on a an investigation into the systemic immune response to a Phase I/II trial (NCT02489448) of durvalumab concomitant with neoadjuvant chemotherapy in early stage triple-negative breast cancer (TNCB). 38 serum cytokines and the peripheral blood T-cell receptor (TCR) immune repertoire of 66 patients with TNBC we evaluated for associations with pathologic complete response (pCR), pre- and post-treatment phase, and immune related treatment emergent adverse events. Specific subsets of cytokines were found to be associated with residual disease and pCR. Additionally, specific immune-related cytokines and chemokines were found to be associated with immune-related adverse events. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.